Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.

Tur C, Montalban X, Tintoré M, Nos C, Río J, Aymerich FX, Brieva L, Téllez N, Perkal H, Comabella M, Galán I, Calle D, Sastre-Garriga J, Rovira A.

Arch Neurol. 2011 Nov;68(11):1421-7. doi: 10.1001/archneurol.2011.241.

PMID:
22084124
2.

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.

Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.

Mult Scler. 2009 Oct;15(10):1195-205. doi: 10.1177/1352458509106937. Epub 2009 Sep 29.

PMID:
19797261
3.

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS.

Neurology. 2004 Nov 23;63(10):1788-95.

PMID:
15557491
4.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators.

Neurology. 2002 Sep 10;59(5):679-87.

PMID:
12221157
5.

[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis].

Zimmermann C, Walther EU, Goebels N, Lienert C, Kappos L, Hartung HP, Hohlfeld R.

Nervenarzt. 1999 Aug;70(8):759-63. German.

PMID:
10483579
6.

Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.

Fernández O, Guerrero M, Mayorga C, Muñoz L, Leán A, Luque G, Hervás M, Fernández V, Capdevila A, de Ramón E.

J Neurol. 2002 Aug;249(8):1058-62.

PMID:
12195454
7.

A reassessment of the plateauing relationship between T2 lesion load and disability in MS.

Sormani MP, Rovaris M, Comi G, Filippi M.

Neurology. 2009 Nov 10;73(19):1538-42. doi: 10.1212/WNL.0b013e3181c06679. Epub 2009 Sep 30.

PMID:
19794123
8.

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

Barkhof F, van Waesberghe JH, Filippi M, Yousry T, Miller DH, Hahn D, Thompson AJ, Kappos L, Brex P, Pozzilli C, Polman CH; European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis.

Brain. 2001 Jul;124(Pt 7):1396-402.

PMID:
11408334
9.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al.

Ann Neurol. 1996 Mar;39(3):285-94. Erratum in: Ann Neurol 1996 Sep;40(3):480.

PMID:
8602746
10.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
11.

[Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].

Mezei Z, Bereczki D, Csiba L, Csépány T.

Ideggyogy Sz. 2006 Nov 20;59(11-12):442-7. Hungarian.

PMID:
17203882
13.
14.

Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study.

Mesaros S, Rocca M, Sormani M, Valsasina P, Markowitz C, De Stefano N, Montalban X, Barkhof F, Ranjeva J, Sailer M, Kappos L, Comi G, Filippi M.

Mult Scler. 2010 Mar;16(3):325-31. doi: 10.1177/1352458509358713. Epub 2010 Jan 19.

PMID:
20086023
15.

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.

Neurology. 2001 May 22;56(10):1324-30.

PMID:
11376182
16.

Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.

Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.

J Neurol. 2003 Sep;250(9):1037-43.

PMID:
14504963
17.

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF.

Neurology. 2004 Mar 9;62(5):719-25.

PMID:
15007120
18.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825
19.

Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.

Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.

Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9.

PMID:
18184917
20.

Supplemental Content

Support Center